Mutation-derived tumor antigens: Novel targets in cancer immunotherapy

John P. Finnigan; Alex Rubinsteyn; Jeffrey Hammerbacher; Nina Bhardwaj

Mutation-derived tumor antigens: Novel targets in cancer immunotherapy

John P. Finnigan, Alex Rubinsteyn, Jeffrey Hammerbacher, Nina Bhardwaj

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Because of the abundance of promising preclinical and early-phase clinical data, mutation-derived tumor antigens an exciting new class of targets in cancer immunotherapy.

Original language	English
Journal	Oncology
Volume	29
Issue number	12
State	Published - 15 Dec 2015

Cite this

@article{9fb6a5d069dc4bd29109b277de5b29c5,

title = "Mutation-derived tumor antigens: Novel targets in cancer immunotherapy",

abstract = "Because of the abundance of promising preclinical and early-phase clinical data, mutation-derived tumor antigens an exciting new class of targets in cancer immunotherapy.",

author = "Finnigan, {John P.} and Alex Rubinsteyn and Jeffrey Hammerbacher and Nina Bhardwaj",

year = "2015",

month = dec,

day = "15",

language = "English",

volume = "29",

journal = "Oncology",

issn = "0890-9091",

publisher = "UBM Medica Healthcare Publications",

number = "12",

}

TY - JOUR

T1 - Mutation-derived tumor antigens

T2 - Novel targets in cancer immunotherapy

AU - Finnigan, John P.

AU - Rubinsteyn, Alex

AU - Hammerbacher, Jeffrey

AU - Bhardwaj, Nina

PY - 2015/12/15

Y1 - 2015/12/15

N2 - Because of the abundance of promising preclinical and early-phase clinical data, mutation-derived tumor antigens an exciting new class of targets in cancer immunotherapy.

AB - Because of the abundance of promising preclinical and early-phase clinical data, mutation-derived tumor antigens an exciting new class of targets in cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84950977112&partnerID=8YFLogxK

M3 - Article

C2 - 26676902

AN - SCOPUS:84950977112

SN - 0890-9091

VL - 29

JO - Oncology

JF - Oncology

IS - 12

ER -

Mutation-derived tumor antigens: Novel targets in cancer immunotherapy

Abstract

Fingerprint

Cite this